公开(公告)号：US20240301364A1

公开(公告)日：2024-09-12

申请号：US18665920

申请日：2024-05-16

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Edward CLARK ,  Jay Wesley CHAPLIN

IPC: C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/385 ,  A61K47/68 ,  C07K16/28

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/385 ,  A61K47/6811 ,  A61K47/6849 ,  C07K16/2896 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/6056 ,  C07K2319/40 ,  C07K2319/74 ,  C12N2770/24132 ,  C12N2770/24134 ,  C12N2770/28033 ,  Y02A50/30

Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

公开(公告)号：US20240182567A1

公开(公告)日：2024-06-06

申请号：US18583551

申请日：2024-02-21

Applicant: National University of Singapore

Inventor： Yi Tian Png ,  Natasha Vinanica ,  Takahiro Kamiya ,  Dario Campana

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61K39/001129 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/3061 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/04 ,  C07K2319/05 ,  C07K2319/33 ,  C07K2319/74

Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

公开(公告)号：US11981731B2

公开(公告)日：2024-05-14

申请号：US16743772

申请日：2020-01-15

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC: A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C12N5/0636 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20240147984A1

公开(公告)日：2024-05-09

申请号：US18279907

申请日：2022-03-03

Applicant: SYNKLINO A/S

Inventor： Mette Marie ROSENKILDE ,  Mads Gravers JEPPESEN ,  Thomas N. KLEDAL

IPC: A01N1/02 ,  C07K14/705

CPC classification number: A01N1/0215 ,  A01N1/0226 ,  A01N1/0231 ,  C07K14/705 ,  C07K2319/74

Abstract: A composition is provided which comprises a fusion protein in an aqueous medium. The fusion protein is able to bind a receptor expressed on a cell, and to kill said cell. The aqueous medium comprises one or more components that enable the treatment of an ex vivo organ, tissue and/or stem cell culture prior to transplantation. The composition is thus useful for the prevention or treatment of an infection caused by a pathogen in an ex vivo organ, tissue and/or stem cell culture.

公开(公告)号：US11952411B2

公开(公告)日：2024-04-09

申请号：US17405872

申请日：2021-08-18

Applicant: JANSSEN BIOTECH, INC.

Inventor： Adam Zwolak ,  Szeman Chan ,  Rajkumar Ganesan

IPC: C07K14/705 ,  A61K38/00 ,  A61P37/04 ,  C07K14/765

CPC classification number: C07K14/70575 ,  A61P37/04 ,  C07K14/765 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74

Abstract: Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.

公开(公告)号：US20240100156A1

公开(公告)日：2024-03-28

申请号：US18166938

申请日：2023-02-09

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K47/68 ,  C07K14/31 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20240084007A1

公开(公告)日：2024-03-14

申请号：US18502993

申请日：2023-11-06

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： Rimas J. Orentas ,  Ira H. Pastan ,  Dimiter S. Dimitrov ,  Crystal L. MacKall

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K16/2803 ,  A61K39/0011 ,  C07K16/3061 ,  C12N5/0638 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/505 ,  C12N2501/599 ,  C12N2510/00

Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

公开(公告)号：US11926652B2

公开(公告)日：2024-03-12

申请号：US15931077

申请日：2020-05-13

Applicant: City of Hope ,  Thomas Jefferson University and Health System, Innovation Pillar

Inventor： John Williams ,  Ulrich Rodeck ,  Miso Park ,  Kurt Jenkins

IPC: C07K14/47 ,  A61K38/00 ,  A61K47/64 ,  A61K47/65 ,  C07K14/705

CPC classification number: C07K14/4703 ,  A61K47/64 ,  A61K47/65 ,  C07K14/70521 ,  A61K38/00 ,  C07K2319/055 ,  C07K2319/30 ,  C07K2319/50 ,  C07K2319/70 ,  C07K2319/74

Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.

公开(公告)号：US11807682B2

公开(公告)日：2023-11-07

申请号：US16869792

申请日：2020-05-08

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Rimas J. Orentas ,  Ira H. Pastan ,  Dimiter S. Dimitrov ,  Crystal L. Mackall

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C12N5/0783 ,  C12N15/62 ,  A61K39/00 ,  C12N15/85 ,  C12N15/63 ,  C12N15/64 ,  C12N15/70

CPC classification number: C07K16/2803 ,  A61K39/0011 ,  C07K16/3061 ,  C12N5/0638 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N15/62 ,  C12N15/625 ,  C12N15/63 ,  C12N15/64 ,  C12N15/70 ,  C12N15/85 ,  C12N2501/505 ,  C12N2501/599 ,  C12N2510/00

Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

公开(公告)号：US20230348934A1

公开(公告)日：2023-11-02

申请号：US18179269

申请日：2023-03-06

Applicant: Ecole Normale Superieure De Lyon ,  Centre National de La Recherche Scientifique (CNRS) ,  Université Claude Bernard Lyon 1 ,  Institut National de la Santé et de la Recherche Medicale (INSERM)

Inventor： Caroline COSTA FEJOZ ,  Els Verhoeyen ,  François-Loîc Cosset ,  Ruben Bender ,  Christian Buchholz ,  Qi Zhou

IPC: C07K16/32 ,  C12N15/86 ,  C07K16/28 ,  A61P35/00 ,  C07K14/005 ,  C07K14/54

CPC classification number: C12N15/86 ,  A61P35/00 ,  C07K14/005 ,  C07K14/5418 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/32 ,  A61K2039/505 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2740/16043 ,  C12N2740/16045 ,  C12N2760/18222 ,  C12N2760/18422

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain.
The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.